Differential expression of leucine rich repeat containing 2 in cancers of the breast.
Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding leucine rich repeat containing 2, LRRC2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. LRRC2 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of LRRC2 in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A, luminal B, and HER2+ subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. LRRC2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.